Navigation Links
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Date:2/11/2008

NEW YORK, Feb. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals announced today that the last subject randomized into the SUN-Micro Phase 3 clinical trial has completed their scheduled 8 month visit. This milestone officially marks the completion of this pivotal clinical trial of its investigational drug Sulonex(TM) (sulodexide oral gelcap) in the treatment of subjects with type 2 diabetes and persistent microalbuminuria despite treatment with the maximum approved or tolerated dose of either an Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB). This randomized, double-blind, placebo-controlled study enrolled 1,056 subjects at over 150 sites worldwide.

The Company anticipates being able to report top-line results from this study before the end of March 2008, and expects that the Collaborative Study Group will make a comprehensive scientific presentation of the data at a medical conference in the 2nd or 3rd quarter. The Company is targeting an NDA filing before year end.

"The completion of the Sulonex Phase 3 clinical program is an important and significant milestone for Keryx," stated Michael S. Weiss, Chairman and CEO of the Company, who continued, "We recognize and are grateful for the dedication, diligence and compliance exhibited by the Collaborative Study Group and the more than 1,000 patients who participated in what is considered to be the largest ever randomized study for type 2 diabetic patients with persistent microalbuminuria."

Commenting on the news, Edmund J. Lewis, MD, co-Principal Investigator of the Phase 3 Study remarked, "We would like to commend both our Investigators and their patients for their level of commitment towards the completion of this pivotal 8-month study, marking the culmination of critical research in a disease area for which there has not been a novel treatment option in almost 15 years. We look forward to assembling and analyzing the data from this study."

A
'/>"/>

SOURCE Keryx Biopharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
4. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014  GenSpera, Inc. (OTCQB: GNSZ), a ... of cancer, announces that Kareg Corporation,s Director of ... the following research report on  the company. ... of Research, Kareg Corporation, Initiating Coverage with a ... full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf GNSZ ...
(Date:7/14/2014)... 2014  Otonomy, Inc., a clinical-stage biopharmaceutical company focused ... diseases and disorders of the inner and middle ear, ... statement on Form S-1 with the U.S. Securities and ... offering of shares of its common stock. All shares ... will be offered by Otonomy. The number of shares ...
(Date:7/14/2014)... and LONDON , July 14, 2014 ... IXICO plc (AIM: IXI) jointly announced today the formation ... companies. Dr. Edward Ashton , Ph.D., chief scientific ... have seven members. "The formation of this ... the international commercial and operational alliance we signed with ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Otonomy Files Registration Statement for Proposed Initial Public Offering 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9
... YORK, Sept. 21 An eminent international panel of ... LLY ) to receive a World Business and ... successful partnerships in the battle against multidrug-resistant tuberculosis (MDR-TB). ... of The Lilly MDR-TB Partnership demonstrate a clear linkage ...
... According to Millennium Research Group (MRG), the global authority ... new growth factors, combined with greater variety and improved features ... market to nearly $2.3 billion through 2015. Medtronic ... AMPLIFY , is set to be released in the US ...
Cached Medicine Technology:Lilly Recognized with World Business and Development Award for Tuberculosis Initiative 2Lilly Recognized with World Business and Development Award for Tuberculosis Initiative 3Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015 2Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015 3
(Date:7/14/2014)... Laurel, N.J. (PRWEB) July 14, 2014 ... Mount Laurel, has announced the publication of its first military ... plane crash on Black Thursday in October 1943 and 19 ... March to return home and build the American dream. ... II and the American dream (Amazon) is a ...
(Date:7/14/2014)... According to a recent study ... a connection between women with high levels of a ... doctors have theorized about the role stress plays in ... provide scientific support. , “Stress, if very significant, can ... Barmat, an OB/GYN who specializes in reproductive endocrinology and ...
(Date:7/14/2014)... There’s an old adage that says first impressions make ... say the products offered in their preorder event not only ... The Lash Palette for $40,” said Jenelle Paris, founder and ... explained that the first 1,000 have already been sold during ... on to point out that her company is an online ...
(Date:7/14/2014)... Jordan Valley Medical Center is expanding the ... center set to open by the fall of 2015. ... west of I-15 in the Salt Lake Valley providing ... Valley Medical Center has partnered with Elekta, a company ... for radiation therapy, radiosurgery and brachytherapy, to bring Versa ...
(Date:7/14/2014)... For the Spanish Royal Academy, senescent is he who ... the dictionary: not only is senescence not a synonym ... the organism. Cellular senescence is such a badly named ... area think it needs another name. That is the ... Research Centre (CNIO), one of the world,s leading experts ...
Breaking Medicine News(10 mins):Health News:Mount Laurel-based Documented Legacy to Release Military Memoir of World War II Air Force Vet Who Survived Black Thursday Crash 2Health News:Abington Health Physician Addresses Link Between Stress and Infertility 2Health News:Abington Health Physician Addresses Link Between Stress and Infertility 3Health News:The Lash Palette Preorder Event Has Officially Begun 2Health News:Jordan Valley Medical Center Set to Break Ground with New $10 Million Cancer Center 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3
... diabetes research in India, even though the country remains one ... disease. Indian scientists have published only one percent of the ... Indian Journal of Medical Research, in an assessment of the ... India published a total of 3068 papers during the 30 ...
... 25 million dollar space programme, will carry out scientific ... cells in outer space, reports said Wednesday. ... and the crystallisation of protein, said Abdul Rahman Abdul ... National University of Malaysia. ,"The research is ...
... their health by using over the counter nutritional supplements ... cons with the health professionals managing their conventional treatment. ... Griffith's School of Nursing, says that though some complementary ... have side effects or interact with conventional medications. ...
... School of Medicine in St. Louis, Missouri, have found ... to treatments for deadliest poisons like Ricin, cholera toxin, ... deadly strains of E. coli bacteria, these toxins travel ... Golgi network and endoplasmic reticulum before interrupting protein synthesis. ...
... a developing female sheep foetus to low doses of commonly ... ,The study was conducted by a team ... of Aberdeen, Scotland, UK. ,As part of the ... a cocktail of chemicals and heavy metals in an animal ...
... New research by the British charity Save the Children, shows ... nutritious diet , they would have to spend three times ... reported by The Independent, this would amount to a 1,700 ... research calculated how much a healthy diet, based on local ...
Cached Medicine News:Health News:India's Share in Global Diabetes Research is One Percent 2Health News:Diabetics Risking Health by Using Alternative Medications Without Consultation 2Health News:For Bangladeshis, a Nutritious Diet Would Cost 1,700 Pounds Per Week 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: